Qynapse

Founded in 2014 and headquartered in Paris, Qynapse operates at the intersection of neuroscience, AI, and digital health. The company has developed a regulatory-cleared (FDA, CE) software platform, QyScore®, which analyzes brain MRI scans to produce precise volumetric and white matter integrity measures, addressing a critical need for objective diagnostics in neurodegenerative diseases. With a focus on reducing misdiagnosis rates and improving patient outcomes, Qynapse targets both clinical care and pharmaceutical R&D, positioning itself as a key enabler in the precision medicine landscape for CNS disorders. Its technology is validated against gold-standard manual segmentation and leverages a large normative dataset.

AI-powered neuroimaging software platform that analyzes MRI scans to produce automated, quantitative biomarkers of neuroinflammation and neurodegeneration. It utilizes 20 proprietary algorithms and a normative dataset of over 10,000 brain scans.

Qynapse competes in the growing market for AI-based medical image analysis, facing competition from other specialized neuroimaging software firms (e.g., icometrix, CorTechs Labs, Brainreader), as well as broader digital pathology and radiology AI platforms. Large tech companies are also entering the healthcare AI space, increasing competitive pressure.